Galvanize Therapeutics said the FDA cleared its Aliya EX Generator for surgical ablation of soft tissue, setting up a limited U.S. commercial release and broadening its Aliya pulsed electric field platform.
Galvanize Therapeutics said the U.S. Food and Drug Administration cleared its Aliya EX Generator for surgical ablation of soft tissue, a regulatory step that expands the company’s Aliya pulsed electric field platform.
The company said the clearance was granted on May 18, 2026. It also said the generator will enter a limited U.S. commercial release.
Trade coverage reported that the new generator expands the Aliya system and is intended to increase ablation volume versus the prior platform. Galvanize described the device as part of its soft-tissue ablation portfolio.
The company has not said exactly when the limited U.S. rollout will begin.
FDA 510(k) clearances do not mean a product is widely available immediately, but they can remove a key barrier to commercialization and broader adoption.
What it means
The clearance gives Galvanize a new regulatory pathway to sell the Aliya EX Generator in the U.S. on a limited basis while it prepares a broader rollout.
Revision note
Initial automated publication.